急性髓系白血病的 Menin 抑制剂：2023 年 ASH 年会最新进展。
Menin inhibitors for acute myeloid leukemia: latest updates from the 2023 ASH Annual Meeting.
机构信息
Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Collaborative Innovation Center of Hematology, Peking University, Beijing, China.
出版信息
J Hematol Oncol. 2024 Jul 19;17(1):52. doi: 10.1186/s13045-024-01573-2.
Recent developments in menin inhibitors for relapsed or refractory acute myeloid leukemia (AML) were highlighted at the 2023 ASH Annual Meeting. Notably, revumenib showed promising efficacy, achieving a 100% ORR when combined with decitabine/cedazuridine and venetoclax. These findings underscore the potential of menin inhibitors in transforming AML treatment, particularly in genetically defined subgroups, offering hope for improved patient outcomes. Ongoing studies, like KOMET-008, further explore the synergistic potential of menin inhibitors in combination regimens, shaping future AML management strategies.
在 2023 年 ASH 年会上强调了 menin 抑制剂在复发性或难治性急性髓系白血病（AML）方面的最新进展。值得注意的是，当与地西他滨/西达本胺和 venetoclax 联合使用时，revumenib 显示出有希望的疗效，达到了 100%的客观缓解率。这些发现强调了 menin 抑制剂在改变 AML 治疗中的潜力，特别是在遗传定义的亚组中，为改善患者预后带来了希望。正在进行的研究，如 KOMET-008，进一步探索了 menin 抑制剂联合方案的协同潜力，为未来的 AML 管理策略提供了依据。
Zotero 插件